The association of genomic alterations with PD‐L1 expression in Chinese patients with EGFR/ALK wild‐type lung adenocarcinoma and potential predictive value of …
F Liu, X Zhang, M Lu, C Liu, X Zhang, Q Chu… - Cancer …, 2024 - Wiley Online Library
Background The study focuses on PD‐L1 expression as an essential biomarker for gauging
the response of EGFR/ALK wild‐type NSCLC patients to FDA‐approved immune checkpoint …
the response of EGFR/ALK wild‐type NSCLC patients to FDA‐approved immune checkpoint …
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer
S Liu, Z Dong, S Wu, Z Xie, L Yan, YF Li, H Yan, J Su… - Lung Cancer, 2018 - Elsevier
Objectives EGFR-mutated or ALK-rearranged non-small cell lung cancer (NSCLC) often
showed unfavorable clinical benefit to checkpoint inhibitors (CPIs). However, few reports …
showed unfavorable clinical benefit to checkpoint inhibitors (CPIs). However, few reports …
[HTML][HTML] Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer
H Chen, M Ge, F Zhang, Y Xing, S Yu, C Chen… - Genomics, 2023 - Elsevier
Abstract Programmed death-ligand 1 (PD-L1) has been widely used in immunotherapy
evaluation of patients with non-small cell lung cancer (NSCLC). However, the effect is not …
evaluation of patients with non-small cell lung cancer (NSCLC). However, the effect is not …
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusion
H Sakai, M Takeda, K Sakai, Y Nakamura, A Ito… - Lung Cancer, 2019 - Elsevier
Abstract Objectives Immune-checkpoint inhibitors (ICIs) are now an established therapeutic
option for advanced non–small cell lung cancer (NSCLC). It has remained unclear, however …
option for advanced non–small cell lung cancer (NSCLC). It has remained unclear, however …
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma
J Biton, A Mansuet-Lupo, N Pécuchet, M Alifano… - Clinical Cancer …, 2018 - AACR
Purpose: By unlocking antitumor immunity, antibodies targeting programmed cell death 1
(PD-1) exhibit impressive clinical results in non–small cell lung cancer, underlining the …
(PD-1) exhibit impressive clinical results in non–small cell lung cancer, underlining the …
Ma15. 10 potential predictive value of Tp53 and Kras mutation status for response to Pd-1 blockade immunotherapy in lung adenocarcinoma
ZY Dong, WZ Zhong, SY Liu, Z Xie, SP Wu… - Journal of Thoracic …, 2017 - jto.org
Background Although clinical studies have shown promise for targeting programmed cell
death protein-1 (PD-1) and ligand (PD-L1) signaling in non-small cell lung cancer (NSCLC) …
death protein-1 (PD-1) and ligand (PD-L1) signaling in non-small cell lung cancer (NSCLC) …
High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
BW Yoon, B Chang, SH Lee - OncoTargets and therapy, 2020 - Taylor & Francis
Purpose Although programmed death-ligand 1 (PD-L1) expression is widely accepted as a
predictive and prognostic biomarker in immunotherapy, its implications in lung cancer …
predictive and prognostic biomarker in immunotherapy, its implications in lung cancer …
B7–H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression
Y Lu, F Wu, Q Cao, Y Sun, M Huang, J Xiao, B Zhou… - Oncogene, 2022 - nature.com
Abstract PD-1/PD-L1 inhibitors have shown clinical benefit in lung adenocarcinoma (LUAD).
However, the immunotherapy strategy is less effective in patients with EGFR-activating …
However, the immunotherapy strategy is less effective in patients with EGFR-activating …
Differences in Immunological Landscape between EGFR‐Mutated and Wild‐Type Lung Adenocarcinoma
JW Luo, YH Guo, FY Wu, XF Li, XC Sun… - Disease …, 2021 - Wiley Online Library
Recent clinical trials of lung adenocarcinoma with immune checkpoint inhibitors revealed
that lung adenocarcinoma patients with EGFR mutations have a poor response to …
that lung adenocarcinoma patients with EGFR mutations have a poor response to …
Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database.
ZHU Guangsheng, LI Yongwen… - Chinese Journal of …, 2021 - search.ebscohost.com
Background and objective Lung cancer is a malignant with high incidence and mortality and
adenocarcinoma is among the most popular subtypes. Epidermal growth factor receptor …
adenocarcinoma is among the most popular subtypes. Epidermal growth factor receptor …
相关搜索
- egfr mutations pd 1
- genomic alterations chinese patients
- pd l1 lung adenocarcinomas
- genomic alterations lung adenocarcinoma
- egfr mutations lung adenocarcinoma
- chinese patients lung adenocarcinoma
- pd l1 immunotherapy biomarker
- pd l1 targeted therapy
- targeted therapy lung adenocarcinomas
- alk fusion egfr mutation
- pd l1 driver alterations
- pd l1 alk fusion
- blockade immunotherapy lung adenocarcinoma
- pd l1 cells infiltration
- pd l1 checkpoint inhibitors
- pd l1 clinical relevance